Crown jew­el in big Gilead buy­out lands break­through des­ig­na­tion for MDS

Months af­ter Gilead snagged ma­grolimab in the $4.9 bil­lion buy­out of Cal­i­for­nia biotech Forty Sev­en — the com­pa­ny’s largest ac­qui­si­tion in three years at the time …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER